Conversely, Oct4-knockdown has been shown to increase the sensitivity to cisplatin treatment and radiotherapy in lung and ovarian cancers and to temozolomide in glioma-initiating cells (88–91). This evidence concerns the gene POU5F1 and ovarian carcinoma.